National Cancer Centre Singapore is excited to partner NCIS to embark on clinical trials
National Cancer Centre Singapore shared a post on LinkedIn:
“With a generous S$12 million commitment from the Li Ka Shing Foundation and Temasek Trust, NCCS is excited to partner NCIS to embark on clinical trials using a non-invasive ultrasound-based technology called histotripsy for patients with liver, kidney, and pancreatic cancers.
In Singapore, liver cancer is the third most common cause of cancer death for men, with liver and pancreatic cancers among the top 10 causes of cancer mortality. These cancers often do not show symptoms until the later stages, making early detection and effective treatment difficult.
Thank you to the Li Ka Shing Foundation and Temasek Trust for the strong support towards advancing cancer research by enabling us to study this innovative technology!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023